recently published research projects
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
A significant number of patients with non-Hodgkin lym-phoma (NHL) are not cured with available treatments and will eventually relapse. Those patients might not be able to tolerate more bone marrow toxicity, limiting their treatment options. Preclinical in vitro studies have demonstrated a synergism of venetoclax and copanlisib in different ...
This is a first-in-human (FIH), open label, phase I/Ib, multi-center study which consists of: - a dose escalation part of NIS793 as single agent and in combination with PDR001. Patients treated with NIS793 single agent will switch to NIS793 in combination with PDR001 either upon disease progression or after 2 cycles whichever is earlier. Dose ...